Alexandria Hammond
Stock Analyst at Wolfe Research
(1.25)
# 3,763
Out of 4,668 analysts
49
Total ratings
50%
Success rate
-1.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alexandria Hammond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Upgraded: Buy | $300 | $221.56 | +35.40% | 2 | Aug 13, 2026 | |
| ABBV AbbVie | Upgraded: Buy | $300 | $265.97 | +12.79% | 3 | Aug 13, 2026 | |
| LLY Eli Lilly and Company | Maintained: Buy | $1,325 → $1,350 | $1,280.34 | +5.44% | 6 | May 21, 2026 | |
| REGN Regeneron Pharmaceuticals | Reiterated: Buy | $1,150 → $860 | $840.84 | +2.28% | 2 | May 18, 2026 | |
| PFE Pfizer | Reiterated: Sell | $25 → $26 | $28.24 | -7.93% | 5 | May 13, 2026 | |
| MRK Merck & Co. | Upgraded: Buy | $135 | $152.20 | -11.30% | 3 | Jan 8, 2026 | |
| MRNA Moderna | Reiterated: Sell | $20 → $17 | $174.38 | -90.25% | 6 | Nov 20, 2025 | |
| JNJ Johnson & Johnson | Maintained: Buy | $200 → $225 | $273.41 | -17.71% | 7 | Oct 15, 2025 | |
| BMRN BioMarin Pharmaceutical | Reiterated: Buy | $95 | $69.33 | n/a | 3 | Jul 15, 2025 | |
| GILD Gilead Sciences | Initiated Coverage: Buy | $110 → $109 | $147.60 | n/a | 3 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $442.36 | n/a | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $67.61 | n/a | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $150 | $540.16 | n/a | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $550 | $552.06 | n/a | 2 | Aug 2, 2024 |
Biogen
Aug 13, 2026
Upgraded: Buy
Price Target: $300
Current: $221.56
Upside: +35.40%
AbbVie
Aug 13, 2026
Upgraded: Buy
Price Target: $300
Current: $265.97
Upside: +12.79%
Eli Lilly and Company
May 21, 2026
Maintained: Buy
Price Target: $1,325 → $1,350
Current: $1,280.34
Upside: +5.44%
Regeneron Pharmaceuticals
May 18, 2026
Reiterated: Buy
Price Target: $1,150 → $860
Current: $840.84
Upside: +2.28%
Pfizer
May 13, 2026
Reiterated: Sell
Price Target: $25 → $26
Current: $28.24
Upside: -7.93%
Merck & Co.
Jan 8, 2026
Upgraded: Buy
Price Target: $135
Current: $152.20
Upside: -11.30%
Moderna
Nov 20, 2025
Reiterated: Sell
Price Target: $20 → $17
Current: $174.38
Upside: -90.25%
Johnson & Johnson
Oct 15, 2025
Maintained: Buy
Price Target: $200 → $225
Current: $273.41
Upside: -17.71%
BioMarin Pharmaceutical
Jul 15, 2025
Reiterated: Buy
Price Target: $95
Current: $69.33
Upside: n/a
Gilead Sciences
Dec 10, 2024
Initiated Coverage: Buy
Price Target: $110 → $109
Current: $147.60
Upside: n/a
Nov 14, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $442.36
Upside: n/a
Nov 14, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $67.61
Upside: n/a
Aug 7, 2024
Reiterated: Sell
Price Target: $150
Current: $540.16
Upside: n/a
Aug 2, 2024
Reiterated: Buy
Price Target: $550
Current: $552.06
Upside: n/a